{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:25:33Z","timestamp":1792481133575,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260914"],"award-info":[{"award-number":["82260914"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02502-6","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:00:52Z","timestamp":1747404052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug-induced second tumors: a disproportionality analysis of the FAERS database"],"prefix":"10.1007","volume":"16","author":[{"given":"Shupeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2502_CR1","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMc2408733","volume":"391","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Miklos DB, Alizadeh AA. Risk of second tumors and t-cell lymphoma after car t-cell therapy: reply. N Engl J Med. 2024;391:870\u20131. https:\/\/doi.org\/10.1056\/NEJMc2408733.","journal-title":"N Engl J Med"},{"key":"2502_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042228","author":"AG Papavassiliou","year":"2024","unstructured":"Papavassiliou AG, Delle Cave D. Novel therapeutic approaches for colorectal cancer treatment. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042228.","journal-title":"Int J Mol Sci"},{"key":"2502_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.dld.2020.09.031","volume":"53","author":"S Massironi","year":"2021","unstructured":"Massironi S, Campana D, Pusceddu S, et al. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: data from a retrospective multi-centric study. Dig Liver Dis. 2021;53:367\u201374. https:\/\/doi.org\/10.1016\/j.dld.2020.09.031.","journal-title":"Dig Liver Dis"},{"key":"2502_CR4","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1182\/blood-2024-203046","volume":"144","author":"A Katsimigas","year":"2024","unstructured":"Katsimigas A, Pedersen LB, Haunstrup T, et al. Excellent clinical outcomes in deeply mutated IGHV chronic lymphocytic leukemia upon fludarabine and cyclophosphamide plus rituximab. Blood. 2024;144:1860. https:\/\/doi.org\/10.1182\/blood-2024-203046.","journal-title":"Blood"},{"key":"2502_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/bjh.19646","volume":"205","author":"G Corazzelli","year":"2024","unstructured":"Corazzelli G, Cuccaro A, Morelli E, et al. Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced hodgkin lymphoma: a 15-year follow-up of the ABVD(DD-DI) phase ii study. Br J Haematol. 2024;205:1383\u20138. https:\/\/doi.org\/10.1111\/bjh.19646.","journal-title":"Br J Haematol"},{"key":"2502_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.annonc.2024.08.2343","volume":"35","author":"J Blay","year":"2024","unstructured":"Blay J, Schiffler C, Bouch\u00e9 O, et al. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized gist at high risk of relapse. Ann Oncol. 2024;35:1157\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2343.","journal-title":"Ann Oncol"},{"key":"2502_CR7","first-page":"293","volume-title":"Advances in cancer research","author":"N Mani","year":"2023","unstructured":"Mani N, Daiya A, Chowdhury R, et al. Epigenetic adaptations in drug-tolerant tumor cells. In: Landry JW, Das SK, Fisher PB, editors., et al., Advances in cancer research. Cambridge: Academic Press; 2023. p. 293\u2013335."},{"key":"2502_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01060-w","author":"Y Drew","year":"2024","unstructured":"Drew Y, Zenke FT, Curtin NJ. Dna damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat Rev Drug Discov. 2024. https:\/\/doi.org\/10.1038\/s41573-024-01060-w.","journal-title":"Nat Rev Drug Discov"},{"key":"2502_CR9","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1182\/blood-2024-201555","volume":"144","author":"MS Davids","year":"2024","unstructured":"Davids MS, Burke JM, Woyach JA, et al. Brave: a phase 2 trial evaluating the efficacy and safety of venetoclax in combination with Bruton\u2019s tyrosine kinase inhibitors in patients with first-line chronic lymphocytic leukemia. Blood. 2024;144:3252\u20137. https:\/\/doi.org\/10.1182\/blood-2024-201555.","journal-title":"Blood"},{"key":"2502_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","volume":"115","author":"D Li","year":"2024","unstructured":"Li D, Wang H, Qin C, et al. Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the fda adverse event reporting system database. Clin Pharmacol Ther. 2024;115:535\u201344. https:\/\/doi.org\/10.1002\/cpt.3139.","journal-title":"Clin Pharmacol Ther"},{"key":"2502_CR11","doi-asserted-by":"publisher","first-page":"1480994","DOI":"10.3389\/fphar.2024.1480994","volume":"15","author":"B Li","year":"2024","unstructured":"Li B, Hu X, Yue Z. Drug-induced hearing disorders: a disproportionality analysis of the faers database. Front Pharmacol. 2024;15:1480994. https:\/\/doi.org\/10.3389\/fphar.2024.1480994.","journal-title":"Front Pharmacol"},{"key":"2502_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323. https:\/\/doi.org\/10.1002\/pds.1001.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2502_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (prrs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2502_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"key":"2502_CR15","doi-asserted-by":"publisher","first-page":"1425171","DOI":"10.3389\/fphar.2024.1425171","volume":"15","author":"Y Fan","year":"2024","unstructured":"Fan Y, Wu T, Xu P, et al. Neratinib safety evaluation: real-world adverse event analysis from the faers database. Front Pharmacol. 2024;15:1425171. https:\/\/doi.org\/10.3389\/fphar.2024.1425171.","journal-title":"Front Pharmacol"},{"key":"2502_CR16","doi-asserted-by":"publisher","first-page":"10637","DOI":"10.1038\/s41598-024-61095-2","volume":"14","author":"AM Oliveira","year":"2024","unstructured":"Oliveira AM, Akkerman HB, Braccini S, et al. A high-resolution large-area detector for quality assurance in radiotherapy. Sci Rep. 2024;14:10637. https:\/\/doi.org\/10.1038\/s41598-024-61095-2.","journal-title":"Sci Rep"},{"key":"2502_CR17","doi-asserted-by":"publisher","first-page":"E321","DOI":"10.1503\/cmaj.161032","volume":"189","author":"SL Smith","year":"2017","unstructured":"Smith SL. War! What is it good for? Mustard gas medicine. CMAJ. 2017;189:E321\u20132. https:\/\/doi.org\/10.1503\/cmaj.161032.","journal-title":"CMAJ"},{"key":"2502_CR18","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2217\/fon-2017-0232","volume":"13","author":"RJ Sullivan","year":"2017","unstructured":"Sullivan RJ. The evolutionary nature of the cancer immunotherapy revolution. Future Oncol. 2017;13:1565\u20137. https:\/\/doi.org\/10.2217\/fon-2017-0232.","journal-title":"Future Oncol"},{"key":"2502_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.725","volume":"5","author":"L Zhou","year":"2024","unstructured":"Zhou L, Zhu J, Liu Y, et al. Mechanisms of radiation-induced tissue damage and response. Medcomm. 2024;5: e725. https:\/\/doi.org\/10.1002\/mco2.725.","journal-title":"Medcomm"},{"key":"2502_CR20","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.3748\/wjg.v30.i33.3810","volume":"30","author":"A Kumar","year":"2024","unstructured":"Kumar A, Saha L. Colorectal cancer cell dormancy: an insight into pathways. World J Gastroenterol. 2024;30:3810\u20137. https:\/\/doi.org\/10.3748\/wjg.v30.i33.3810.","journal-title":"World J Gastroenterol"},{"key":"2502_CR21","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.2147\/JMDH.S495330","volume":"17","author":"S Chen","year":"2024","unstructured":"Chen S, Liu J, He G, et al. Research hotspots and trends in global cancer immunometabolism:a bibliometric analysis from 2000 to 2023. J Multidiscip Healthc. 2024;17:5117\u201337. https:\/\/doi.org\/10.2147\/JMDH.S495330.","journal-title":"J Multidiscip Healthc"},{"key":"2502_CR22","doi-asserted-by":"publisher","first-page":"121877","DOI":"10.1016\/j.lfs.2023.121877","volume":"328","author":"G Cao","year":"2023","unstructured":"Cao G, Lin M, Gu W, et al. The rules and regulatory mechanisms of foxo3 on inflammation, metabolism, cell death and aging in hosts. Life Sci. 2023;328:121877. https:\/\/doi.org\/10.1016\/j.lfs.2023.121877.","journal-title":"Life Sci"},{"key":"2502_CR23","doi-asserted-by":"publisher","first-page":"2433904","DOI":"10.1080\/16078454.2024.2433904","volume":"29","author":"S Chen","year":"2024","unstructured":"Chen S, He G, Zhang M, et al. Causal relationship between branched-chain amino acids and leukemia risk: insights from a two-sample mendelian randomization study. Hematology. 2024;29:2433904. https:\/\/doi.org\/10.1080\/16078454.2024.2433904.","journal-title":"Hematology"},{"key":"2502_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The dna damage response: making it safe to play with knives. Mol Cell. 2010;40:179\u2013204. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019.","journal-title":"Mol Cell"},{"key":"2502_CR25","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/leu.2016.20","volume":"30","author":"MB Miranda","year":"2016","unstructured":"Miranda MB, Lauseker M, Kraus M, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in cml study iv. Leukemia. 2016;30:1255\u201362. https:\/\/doi.org\/10.1038\/leu.2016.20.","journal-title":"Leukemia"},{"key":"2502_CR26","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1073\/pnas.1416418112","volume":"112","author":"MS Poruchynsky","year":"2015","unstructured":"Poruchynsky MS, Komlodi-Pasztor E, Trostel S, et al. Microtubule-targeting agents augment the toxicity of dna-damaging agents by disrupting intracellular trafficking of dna repair proteins. Proc Natl Acad Sci USA. 2015;112:1571\u20136. https:\/\/doi.org\/10.1073\/pnas.1416418112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2502_CR27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1677\/erc.1.01191","volume":"13","author":"E Ferrante","year":"2006","unstructured":"Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer. 2006;13:955\u201362. https:\/\/doi.org\/10.1677\/erc.1.01191.","journal-title":"Endocr Relat Cancer"},{"key":"2502_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/bjc.1984.143","volume":"50","author":"N Babudri","year":"1984","unstructured":"Babudri N, Pani B, Tamaro M, et al. Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells. Br J Cancer. 1984;50:91\u20136. https:\/\/doi.org\/10.1038\/bjc.1984.143.","journal-title":"Br J Cancer"},{"key":"2502_CR29","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1111\/cts.13098","volume":"14","author":"S Uzu","year":"2021","unstructured":"Uzu S, Sekine S, Asano J, et al. Assessment of the impact of japanese-specific long-term safety data on new drug approval. Clin Transl Sci. 2021;14:2339\u201347. https:\/\/doi.org\/10.1111\/cts.13098.","journal-title":"Clin Transl Sci"},{"key":"2502_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2146\/ajhp100019","volume":"68","author":"C Meyer-Massetti","year":"2011","unstructured":"Meyer-Massetti C, Cheng CM, Schwappach DLB, et al. Systematic review of medication safety assessment methods. Am J Health Syst Pharm. 2011;68:227\u201340. https:\/\/doi.org\/10.2146\/ajhp100019.","journal-title":"Am J Health Syst Pharm"},{"key":"2502_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.lfs.2004.05.040","volume":"76","author":"H Mizutani","year":"2005","unstructured":"Mizutani H, Tada-Oikawa S, Hiraku Y, et al. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 2005;76:1439\u201353. https:\/\/doi.org\/10.1016\/j.lfs.2004.05.040.","journal-title":"Life Sci"},{"key":"2502_CR32","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-22-0744","volume":"28","author":"Z Qureshy","year":"2022","unstructured":"Qureshy Z, Li H, Zeng Y, et al. Stat3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clin Cancer Res. 2022;28:4737\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0744.","journal-title":"Clin Cancer Res"},{"key":"2502_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.4103\/0973-1482.151861","volume":"12","author":"Y Shen","year":"2016","unstructured":"Shen Y, Zhang X, Chen X, et al. Octreotide reverses the resistance of a2780\/pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro. J Cancer Res Ther. 2016;12:657\u201362. https:\/\/doi.org\/10.4103\/0973-1482.151861.","journal-title":"J Cancer Res Ther"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02502-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:00:53Z","timestamp":1747404053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02502-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2502"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02502-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent were not required as this study was based on publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"786"}}